[CORRECTION ENERGY DEFICIENT STATES AS POSSIBLE PERIOPERATIVE ADAPTATION OF CANCER HEPATOPANCREATODUODENAL ZONE...

Area of Science:

• Oncology
• Anesthesiology
• Critical Care Medicine

Background:

• Perioperative hypoxia is a significant concern in patients undergoing surgery for hepatopancreatoduodenal malignancies.
• Effective management of energy-deficient states and organ hypoxia is crucial for improving patient outcomes.

Purpose of the Study:

• To evaluate the role of remaxol in the complex intensive therapy of perioperative hypoxia in patients with hepatopancreatoduodenal malignancies.
• To assess the impact of remaxol on energy metabolism, oxygen transport, and adaptive responses.

Main Methods:

• A randomized controlled trial involving 48 patients with hepatopancreatoduodenal malignancies.
• Patients were divided into a study group (n=26) receiving remaxol infusion and a control group (n=22) without antihypoxants.
• Assessment included SAPS II and APACHE II scores, oxygen transport, lactate levels, and peripheral blood analysis.

Main Results:

• Remaxol administration was associated with reduced hypoxia and improved oxygen delivery and consumption.
• The treatment group showed better restoration of adaptive physiological reactions compared to the control group.
• Remaxol contributed to mitigating energy-deficient states and organ hypoxia.

Conclusions:

• Remaxol is a valuable component in the perioperative intensive therapy for patients with hepatopancreatoduodenal malignancies.
• Its use promotes better tissue oxygenation and supports the recovery of adaptive mechanisms.
• Remaxol therapy can help reduce various forms of hypoxia in this patient population.